Galapagos NV
Identification and validation of disease modifying drug targets by functional screening in human disease models
Galapagos is a privately held target discovery company established in 1999 and has raised €32 million since its inception. It was formed as a joint venture company by Crucell NV (Netherlands) and Tibotec NV (Netherlands). In the last years Galapagos has entered alliances with a number of companies including Bayer, Euroscreen, Incyte Genomics, Pfizer, Procter & Gamble and Vertex Pharmaceuticals.
Onno van de Stolpe, CEO
Leo Steenbergen, CFO
Graham Dixon, Ph.D., Senior VP Drug Discovery
Andre Hoekema, Ph.D. - Senior VP Corporate Development
Richard Neale, Senior VP North America
Chris Newton, Ph.D., Senior VP BioFocus DPI
David Phillips, Senior VP Sales & Marketing
Dirk Pollet, Ph.D., Senior VP Licensing & Intellectual Property
Raj Parekh, Ph.D., Chairman
Onno van de Stolpe
Ferdinand Verdonck
Laurent Ganem, M.D.
Barry Ross, Ph.D.
Harrold van Barlingen, Ph.D.
Henry Geoffrey (Geoff) McMillan
Rudi Pauwels, Ph.D.
Industriepark Mechelen Noord
Generaal De Wittelaan L11 A3
2800 Mechelen
Belgium
Phone: +32-1534-2900
Fax: +32-1534-2901
Research activities are focused on internal programmes in osteoporosis, rheumatoid arthritis, osteoarthritis and Alzheimer’s disease. Galapagos has developed an integrated, high throughput, biological platform using knock-down (SilenceSelect) and knock-in (FLeXSelect and PhenoSelect) libraries to functionally select new targets. The PhenoSelect™ Library contains over 100,000 arrayed adenovirus genes originated from human placental tissue and is well suited to produce large numbers of secreted proteins and peptides that are potential ligands of orphan G-protein coupled receptors (GPCRs). FLeXSelect is an arrayed adenoviral collection containing full-length cDNAs of genes interesting for small molecule drug development and the development of protein therapeutics.
Galapagos also offers its functional screening platform to external collaborating partners and is also suited for nutraceutical discovery projects. In addition, Galapagos has developed and validated various high throughput, human primary cell based models of disease that are ideal for nutraceutical compound discovery in Alzheimer’s disease, osteoporosis, rheumatoid arthritis, osteoarthritis and asthma. The company’s proprietary adenovirus-based gene expression collections are used to screen collections of human genes in order to identify those targets that are rate limiting in key disease pathways.
With regard to nutraceuticals Galapagos has developed and validated a number of high throughput, human primary cell based models of disease that are ideal for nutraceutical compound discovery in Alzheimer’s disease, osteoporosis, rheumatoid arthritis, osteoarthritis, asthma and type-II diabetes.
The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.
Related patents
- Imidazolopyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases
- Molecular Targets and Compounds, and Methods to Identify the Same, Useful in the Treatment of Joint Degenerative and Inflammatory Diseases
- Nitrogen Heteroaromatic Compounds Which Bind to the Active Site of Protein Kinase Enzymes
- Methods for Identification, and Compounds Useful for the Treatment of Degenerative & Inflammatory Diseases
- Methods and Compositions to Promote Bone Homeostasis
- Methods and Means for Treatment of Osteoarthritis
- Methods for Inducing Differentiation of Undifferentiated Mammalian Cells into Osteoblasts
- Methods, Agents, and Compound Screening Assays for Inducing Differentiation of Undifferentiated Mammalian Cells into Osteoblasts
- Methods, Compositions and Compound Assays for Inhibiting Amyloid-beta Protein Production
- Novel Targets ad Compounds Useful in the Treatment and/or Prophylaxis of a Cardiovascular Disorder, Dyslipidemia and Atherosclerosis, and Methods to Identify Such Compounds
- Nitrogen Heteroaromatic Compounds which Bind to the Active Site of Protein Kinase Enzymes
- Methods and Compositions to Promote Bone Homeostasis
- Methods for Inducing Differentiation of Undifferentiated Mammalian Cells into Osteoblasts
- Novel Targets and Compounds Useful in the Treatment of a Cardiovascular Disorder, Dyslipidemia and Atherosclerosis, and Methods to Identify such Compounds
- The Claimed Invention Relates to Novel 4-Piperidinecarboxamide and the Use Thereof for the Preparation of Medicaments against 5-HT2A Receptor-related Disorders
- Imidazo 1,5-a Pyridine or Imidazo 1,5-a Piperidine Derivatives and Their Use for the Preparation of Medicament Against 5-HT2a Receptor-related Disorders
- Molecular Targets and Compounds, and Methods to Identify the Same, Useful in the Treatment of Joint Degenerative and Inflammatory Diseases
- Modulators of Bone Homeostasis Identified in a High-throughput Screen
- siRNA Knockout Assay Method and Constructs
- High Throughput Screening of Gene Function Using Adenoviral Libraries for Functional Genomics Applications
- Modulators of Bone Homeostasis Identified in a High-throughput Screen
- Adenoviral Library Assay for E2F Regulatory Genes and Methods and Compositions for Screening Compounds
- High Throughput Identification of Modulators of Angiogenesis
- High-throughput Identification of Modulators of E2f Activity
- Modulators of Bone Homeostatis Identifies in a High-throughput Screen
- High-Throughput Screening of Gene Function Using Libraries for Functional Genomics Applications
- High-throughput Screening of Gene Function Using Libraries for Functional Genomics Applications